Cited by 1,137Computational Drug Discovery MethodsChemical Synthesis and AnalysisProtein Degradation and Inhibitors

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Open access

Scott, Duncan E., Bayly, Andrew R., Abell, Chris, Skidmore, John·2016·Nature Reviews Drug Discovery

DOI 10.1038/nrd.2016.29

Open this paper in CoChat — free account Open PDF

Abstract

Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biological systems and are consequently implicated in the development of disease states. Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of medicinal chemists to develop inhibitors, and the first PPI inhibitors have reached clinical development. In this Review, we describe the research leading to these breakthroughs and highlight the existence of groups of structurally related PPIs within the PPI target class. For each of these groups, we use examples of successful discovery efforts to illustrate the research strategies that have proved most useful.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd.2016.29

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 4,196
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored
Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A. C., Mínguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq973 · Cited by 3,469
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Principles of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S. I., & Price, D. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 2,034
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988

Flagged first, then by citations

Show all 172 references

Sorted by citations

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“591 Additionally, another Keap1-Nrf2 PPI inhibitor 74 , which combined conformational features signi ﬁ cantly similar to the Keap1-Nrf2 ETGE complex, revealed the unique inhibition mechanism and provided an innovative strategy for the development of new Keap1-Nrf2 PPI inhibitors.”
Background
Electrochemical strategies for C–H functionalization and C–N bond formation
Kärkäs, M. D. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00619e · Cited by 1,013
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Machine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 893
Roles of METTL3 in cancer: mechanisms and therapeutic targeting
Zeng, C., Huang, W., Li, Y., & Weng, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00951-w · Cited by 645
Spirocyclic Scaffolds in Medicinal Chemistry
Hiesinger, K., Dar’in, D. V., Proschak, E., & Krasavin, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01473 · Cited by 633
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Saikia, S., & Bordoloi, M. (2018) · Current Drug Targets · doi:10.2174/1389450119666181022153016 · Cited by 581
Molecular photoswitches in aqueous environments
Volarić, J., Szymański, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 452
Clinical targeting of HIV capsid protein with a long-acting small molecule
Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A. S., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 455
Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, Mechanism, and Applications
Johansson, J. R., Beke‐Somfai, T., Stålsmeden, A. S., & Kann, N. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00466 · Cited by 413
Overcoming Endosomal Entrapment in Drug Delivery
Pei, D., & Buyanova, M. Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00778 · Cited by 418
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X., Liu, Y., He, G., Peng, C. Y., & Li, J. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 409
Deep learning in bioinformatics: Introduction, application, and perspective in the big data era
Li, Y., Huang, C., Ding, L., Li, Z., Pan, Y., & Gao, X. (2019) · Methods · doi:10.1016/j.ymeth.2019.04.008 · Cited by 401
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 351
Complete protein–protein association kinetics in atomic detail revealed by molecular dynamics simulations and Markov modelling
Plattner, N., Doerr, S., Fabritiis, G. D., & Noé, F. (2017) · Nature Chemistry · doi:10.1038/nchem.2785 · Cited by 344
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes‐McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 373
The post-translational modification, SUMOylation, and cancer (Review)
Han, Z., Feng, Y.-H., Gu, B.-H., Li, Y., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 358
WD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Therapeutic strategies targeting FOXO transcription factors
Calissi, G., Lam, E. W. ‐., & Link, W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0088-2 · Cited by 339
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347
RNA Display Methods for the Discovery of Bioactive Macrocycles
Huang, Y., Wiedmann, M. M., & Suga, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00430 · Cited by 320
How Big Is Too Big for Cell Permeability?
Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303
Artificial intelligence in drug design
Zhong, F., Xing, J., Li, X., Liu, X., Fu, Z., Xiong, Z., Lu, D., Wu, X., Zhao, J., Tan, X., et al. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9342-2 · Cited by 293
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Birkinshaw, R. W., Gong, J., Luo, C. S., Lio, D. S. S., White, C. A., Anderson, M. A., Blombery, P. A., Lessène, G., Majewski, I. J., Thijssen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10363-1 · Cited by 273
Small-molecule discovery through DNA-encoded libraries
Peterson, A. A., & Liu, D. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00713-6 · Cited by 277
NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma
McKee, C. M., & Coll, R. C. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0720-513r · Cited by 246
Bypassing Endocytosis: Direct Cytosolic Delivery of Proteins
Du, S., Liew, S. S., Li, L., & Yao, S. Q. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06584 · Cited by 225
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S.-D., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 241
Improving oral bioavailability of cyclic peptides by N-methylation
Räder, A. F. B., Reichart, F., Weinmüller, M., & Kessler, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.031 · Cited by 222
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09358-9 · Cited by 217
Efficient targeted degradation via reversible and irreversible covalent PROTACs
Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N. (2020) · doi:10.26434/chemrxiv.11494398.v1 · Cited by 213
Unifying principles of bifunctional, proximity-inducing small molecules
Gerry, C. J., & Schreiber, S. L. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0469-1 · Cited by 199
Genome mining methods to discover bioactive natural products
Bauman, K. D., Butler, K. S., Moore, B. S., & Chekan, J. R. (2021) · Natural Product Reports · doi:10.1039/d1np00032b · Cited by 201
Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development
Buckton, L. K., Rahimi, M. N., & McAlpine, S. R. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201905385 · Cited by 195
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
Tanada, M., Tamiya, M., Matsuo, A., Chiyoda, A., Takano, K., Ito, T., Irie, M., Kotake, T., Takeyama, R., Kawada, H., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03886 · Cited by 188
Macrocycles as protein–protein interaction inhibitors
Dougherty, P. G., Qian, Z., & Pei, D. (2017) · Biochemical Journal · doi:10.1042/bcj20160619 · Cited by 181
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2 S ,4 R )-1-(( S )-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)
Soares, P., Gadd, M. S., Frost, J., Galdeano, C., Ellis, L. C. J., Epemolu, O., Rocha, S., Read, K. D., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00675 · Cited by 182
Low-Temperature Plasma for Biology, Hygiene, and Medicine: Perspective and Roadmap
Laroussi, M., Bekeschus, S., Keidar, M., Bogaerts, A., Fridman, A., Lu, X., Ostrikov, K., Hori, M., Stapelmann, K., Miller, V., et al. (2021) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2021.3135118 · Cited by 174
PeSTo: parameter-free geometric deep learning for accurate prediction of protein binding interfaces
Krapp, L. F., Abriata, L. A., Rodríguez, F. C., & Peraro, M. D. (2023) · Nature Communications · doi:10.1038/s41467-023-37701-8 · Cited by 181
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
The many faces of compartmentalized PKA signalosomes
Torres‐Quesada, O., Mayrhofer, J. E., & Stefan, E. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.05.012 · Cited by 167
Orally Active Peptides: Is There a Magic Bullet?
Räder, A. F. B., Weinmüller, M., Reichart, F., Schumacher‐Klinger, A., Merzbach, S., Gilon, C., Hoffman, A., & Kessler, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807298 · Cited by 163
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 162
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 161
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Protein–Small Molecule Interactions in Native Mass Spectrometry
Bennett, J. L., Nguyen, G. T. H., & Donald, W. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00293 · Cited by 161
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 162
Proteomimetics as protein-inspired scaffolds with defined tertiary folding patterns
Horne, W. S., & Grossmann, T. N. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0420-9 · Cited by 153
Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 147
Conversion and degradation pathways of sulfoximines
Wiezorek, S., Lamers, P., & Bolm, C. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00483a · Cited by 141
De novo development of small cyclic peptides that are orally bioavailable
Merz, M. L., Habeshian, S., Li, B., David, J.-A. G. L., Nielsen, A. L., Ji, X., Khwildy, K. I., Benitez, M. M. D., Phothirath, P., & Heinis, C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01496-y · Cited by 161
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00698 · Cited by 139
Pharmacological Targeting of IRE1 in Cancer
Raymundo, D. P., Doultsinos, D., Guillory, X., Carlesso, A., Eriksson, L. A., & Chevet, É. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.07.006 · Cited by 136
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
Cruz-Migoni, A., Canning, P., Quevedo, C. E., Bataille, C. J. R., Béry, N., Miller, A., Russell, A. J., Phillips, S. E. V., Carr, S. B., & Rabbitts, T. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811360116 · Cited by 135
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 286
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Quevedo, C. E., Cruz-Migoni, A., Béry, N., Miller, A., Tanaka, T. U., Petch, D., Bataille, C. J. R., Lee, L. Y. W., Fallon, P. S., Tulmin, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05707-2 · Cited by 134
Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands
Cummings, M. D., & Sekharan, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01985 · Cited by 134
Radius measurement via super-resolution microscopy enables the development of a variable radii proximity labeling platform
Oakley, J. V., Buksh, B. F., Fernández, D. F., Oblinsky, D. G., Seath, C. P., Geri, J. B., Scholes, G. D., & MacMillan, D. W. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203027119 · Cited by 135
Peptide Macrocyclization Inspired by Non-Ribosomal Imine Natural Products
Malins, L. R., deGruyter, J. N., Robbins, K. J., Scola, P. M., Eastgate, M. D., Ghadiri, M. R., & Baran, P. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b01624 · Cited by 126
Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium( iii ) metal-based compound
Liu, L., Wang, W., Huang, S., Hong, Y., Li, G., Lin, S., Tian, J., Cai, Z., Wang, H.-M. D., Ma, D., et al. (2017) · Chemical Science · doi:10.1039/c7sc00311k · Cited by 127
Inhibition of RNA-binding proteins with small molecules
Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 130
Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?
Ivanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 125
NMR as a “Gold Standard” Method in Drug Design and Discovery
Emwas, A.-H. M., Szczepski, K., Poulson, B. G., Chandra, K., McKay, R. T., Dhahri, M., Alahmari, F., Jaremko, Ł., Lachowicz, J. I., & Jaremko, M. (2020) · Molecules · doi:10.3390/molecules25204597 · Cited by 137
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 119
Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
Macalino, S. J. Y., Basith, S., Clavio, N. A. B., Chang, H., Kang, S., & Choi, S. (2018) · Molecules · doi:10.3390/molecules23081963 · Cited by 114
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
Hydroxyl-Group-Dominated Graphite Dots Reshape Laser Desorption/Ionization Mass Spectrometry for Small Biomolecular Analysis and Imaging
Shi, R., Dai, X., Li, W., Lü, F., Liu, Y., Qu, H., Li, H., Chen, Q., Tian, H., Wu, E., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b05328 · Cited by 112
Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein
Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 110
Disease modification in inflammatory skin disorders: opportunities and challenges
Bieber, T. R. M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00735-0 · Cited by 120
Design principles for cyclin K molecular glue degraders
Kozicka, Z., Suchyta, D. J., Focht, V., Kempf, G., Petzold, G., Jentzsch, M., Zou, C., Di Genua, C., Donovan, K. A., Coomar, S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01409-z · Cited by 113
Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 130
Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
Site-Directed Fragment-Based Screening for the Discovery of Protein–Protein Interaction Stabilizers
Sijbesma, E., Hallenbeck, K. K., Leysen, S., de Vink, P. J., Skóra, L., Jahnke, W., Brunsveld, L., Arkin, M. R., & Ottmann, C. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11658 · Cited by 110
Network analysis and in silico prediction of protein–protein interactions with applications in drug discovery
Murakami, Y., Tripathi, L. P., Prathipati, P., & Mizuguchi, K. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.02.005 · Cited by 110
Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1–Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases
Pallesen, J. S., Tran, K. T., & Bach, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00358 · Cited by 112
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives
Cong, H., Xu, L., Wu, Y., Qu, Z., Bian, T., Zhang, W., Xing, C., & Zhuang, C. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01668 · Cited by 119
PDZ Domains as Drug Targets
Christensen, N. R., Čalyševa, J., Fernandes, E. F. A., Lüchow, S., Clemmensen, L. S., Haugaard‐Kedström, L. M., & Strømgaard, K. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800143 · Cited by 114
Tracking chromatin state changes using nanoscale photo-proximity labelling
Seath, C. P., Burton, A. J., Sun, X., Lee, G., Kleiner, R. E., MacMillan, D. W. C., & Muir, T. W. (2023) · Nature · doi:10.1038/s41586-023-05914-y · Cited by 115
Dengue drug discovery: Progress, challenges and outlook
Lim, S. P. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.12.016 · Cited by 110
Hot-spot analysis for drug discovery targeting protein-protein interactions
Rosell, M., & Fernández-Recio, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1430763 · Cited by 105
Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
Li, Q., & Kang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155262 · Cited by 103
Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein-Protein Interaction–a Mechanism that can Contribute to its Antiviral Activity Against COVID-19
Bojadzic, D., Alcazar, O., & Buchwald, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600372 · Cited by 105
Artificial Intelligence (AI) in Drugs and Pharmaceuticals
Sahu, A., Mishra, J., & Kushwaha, N. (2021) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666211207153943 · Cited by 112
Bifunctional chemical probes inducing protein–protein interactions
Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100
Identifying hydrophobic protein patches to inform protein interaction interfaces
Rego, N. B., Xi, E., & Patel, A. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018234118 · Cited by 97
Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space
Poongavanam, V., Doak, B. C., & Kihlberg, J. O. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.010 · Cited by 97
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Genetic Code Expansion: Recent Developments and Emerging Applications
Huang, Y., Zhang, P., Wang, H., Chen, Y., Liu, T., & Luo, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00216 · Cited by 109
Aromatic clusters in protein–protein and protein–drug complexes
Lanzarotti, E., Defelipe, L. A., Marti, M. A., & Turjanski, A. G. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00437-4 · Cited by 102
Reactive intermediates for interactome mapping
Seath, C. P., Trowbridge, A., Muir, T. W., & MacMillan, D. W. C. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01366h · Cited by 91
Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?
Poongavanam, V., Danelius, E., Peintner, S., Alcaraz, L., Caron, G., Cummings, M. D., Wlodek, S. T., Erdélyi, M., Hawkins, P. C. D., Ermondi, G., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b01379 · Cited by 91
Predicting and Experimentally Validating Hot-Spot Residues at Protein–Protein Interfaces
Ibarra, A. Á., Bartlett, G. J., Hegedüs, Z., Dutt, S., Hóbor, F., Horner, K. A., Hetherington, K., Spence, K., Nelson, A. S., Edwards, T. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00560 · Cited by 90
dMM-PBSA: A New HADDOCK Scoring Function for Protein-Peptide Docking
Spiliotopoulos, D., Kastritis, P. L., Melquiond, A. S. J., Bonvin, A. M. J. J., Musco, G., Rocchia, W., & Spitaleri, A. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00046 · Cited by 90
Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing
Wang, Z., Zhou, M., & Arnold, C. W. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa437 · Cited by 91

Authors: Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J.
Affiliations: University of Cambridge (GB)
Corresponding author: Abell, Chris
Skidmore, John
ORCID: Scott, Duncan E.
Bayly, Andrew R.
Abell, Chris
Skidmore, John
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2016-04-11
Volume: 15
Issue: 8
Pages: 533-550
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd.2016.29
OpenAlex: W2329592726
Cited by: 1,137
References: 172
Citations by year: 2026: 101 · 2025: 121 · 2024: 120 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 120 · 2019: 106 · 2018: 107 · 2017: 83 · 2016: 16
FWCI: 8.11
Type: journal article
Language: en
Open access: green
www.repository.cam.ac.uk
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Apollo (University of Cambridge) (submittedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: protein-protein interaction, PPI inhibitors, small molecule drug discovery, drug target identification, structure-based drug design
MeSH terms: Animals, Humans, Models, Molecular, Proteins, Protein Structure, Tertiary, Computational Biology, Protein Interaction Domains and Motifs, Small Molecule Libraries, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks